AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)
Cancer Research UK
Burton Hospitals NHS Foundation Trust

      This study is looking at a new drug called AZD4547 which is being tested for the treatment of
      oestrogen receptor positive breast cancer. AZD4547 is a drug which specifically "blocks"
      proteins called fibroblast growth factor receptors (FGFR1) that are involved in the processes
      that help cancer cells to grow. These proteins may also be responsible for the development of
      resistance to hormonal therapies used to treat some breast cancers. AZD4547 is not yet
      approved for use in breast cancer and is therefore being used in this study as a research
      drug.

      The investigators will also test the theory that it is not necessary for high levels of FGFR1
      to be present in the body to see benefit from AZD4547. (Stage 1 only)
    
Drug